- Home
- SLGL vs SIGA Comparison
SLGL vs SIGA Comparison
Compare SLGL & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGL | SIGA |
|---|---|---|
| Founded | 1997 | 1995 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 223.8M |
| IPO Year | 2016 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SLGL | SIGA |
|---|---|---|
| Price | $70.39 | $3.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $110.00 | N/A |
| AVG Volume (30 Days) | 57.5K | ★ 663.0K |
| Earning Date | 05-22-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $223.84 | $224.81 |
| P/E Ratio | ★ N/A | $24.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.15 | $2.83 |
| 52 Week High | $97.97 | $9.45 |
Technical Indicators
Market Signals| Indicator | SLGL | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 40.03 | 51.68 |
| Support Level | $67.89 | $2.87 |
| Resistance Level | $81.18 | $4.84 |
| Average True Range (ATR) | 5.13 | 0.13 |
| MACD | -1.16 | 0.05 |
| Stochastic Oscillator | 17.86 | 76.25 |
Price Performance
Historical ComparisonAbout SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.